Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
10:29pm, Saturday, 29'th May 2021
New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are
Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients
12:00pm, Friday, 28'th May 2021
Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. The patients were p
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
08:45am, Friday, 28'th May 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeuti
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
10:48pm, Saturday, 22'nd May 2021
New York, New York--(Newsfile Corp. - May 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
11:16am, Friday, 21'st May 2021
The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
Omeros's Narsoplimab US Application Review Pushed By 3 Months, Shares Drop
10:00am, Thursday, 20'th May 2021
Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangio
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
08:45am, Thursday, 20'th May 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeuti
Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call Transcript
10:03pm, Monday, 10'th May 2021
Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call Transcript
Omeros: Q1 Earnings Insights
04:53pm, Monday, 10'th May 2021
Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to ($0.57), which were i
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
08:45am, Wednesday, 05'th May 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 202
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
05:45am, Tuesday, 04'th May 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10)
Omeros: The Prize Is Nigh
09:34pm, Sunday, 18'th Apr 2021
FDA action approving narsoplimab in treatment of HSCT-TMA in Omeros' upcoming PDUFA date has the potential to vault Omeros into multibagger territory overnight. Omeros' narsoplimab in treatment of sev
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
08:45am, Tuesday, 23'rd Mar 2021
SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial beg
Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript
09:35pm, Monday, 01'st Mar 2021
Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript
Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates
06:12pm, Monday, 01'st Mar 2021
Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
